Search Within

Roisin Eilish O'Cearbhaill

Formats
  1. Meeting Abstract (127)
  2. Journal Article (124)
  3. Review (9)
  4. Editorial (6)
  5. Book Section (3)
  6. Guidelines (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (272)
  2. GDMT, Medicine (272)
  3. Gynecologic Medicine Service (272)
  4. Gynecology Disease Management Team (272)
  5. Hematologic Malignancies, Division of (272)
  6. Solid Tumor Oncology Division (272)

More Groups

People
  1. Carol Aghajanian (99)
  2. Alexia Iasonos (75)
  3. Qin Zhou (68)
  4. Rachel Grisham (68)
  5. Dennis Chi (67)
  6. William Tew (66)

More People

Years
  1. 2025 (14)
  2. 2024 (30)
  3. 2023 (43)
  4. 2022 (31)
  5. 2021 (25)
  6. 2020 (41)

More Years

Publications
  1. Gynecologic Oncology (91)
  2. Journal of Clinical Oncology (45)
  3. International Journal of Gynecological Cancer (39)
  4. Annals of Oncology (13)
  5. Gynecologic Oncology Reports (11)
  6. Clinical Cancer Research (9)

More Publications

Publishers
  1. Elsevier Inc. (98)
  2. American Society of Clinical Oncology (48)
  3. Lippincott Williams & Wilkins (40)
  4. American Association for Cancer Research (13)
  5. Oxford University Press (13)
  6. Elsevier B.V. (11)

More Publishers

Results (272)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers
    Journal Article

    Moufarrij, S.; O'Cearbhaill, R. E.; Zhou, Q.; Iasonos, A.; Mantha, S.; Zwicker, J.; Wilkins, C. R.
    Gynecologic Oncology Reports (2024)

    Fulltext@MSK | Save
  • Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: A case series
    Journal Article

    Sia, T. Y.; Wan, V.; Finlan, M.; Zhou, Q. C.; Iasonos, A.; Zivanovic, O.; Sonoda, Y.; Chi, D. S.; Long Roche, K.; Jewell, E.; more...
    International Journal of Gynecological Cancer (2024)

    Fulltext@MSK | Save
  • Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer
    Journal Article

    Ehmann, S.; Lam, C.; Zhou, Q.; Iasonos, A.; Grisham, R. N.; Tew, W. P.; O'Cearbhaill, R. E.; Long Roche, K.; Zivanovic, O.; Sonoda, Y.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival
    Journal Article

    Kahn, R. M.; Selenica, P.; Boerner, T.; Roche, K. L.; Xiao, Y.; Sia, T. Y.; Maio, A.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1/2 study of galinpepimut-S plus pembrolizumab combination in patients with WT1+platinum-resistant ovarian cancer in 2nd/3rd line of therapy
    Meeting Abstract

    Ocearbhaill, R.; Holmes, J.; Bastos, B.; Fu, S. Q.; Muenzen, R.; Cohen, J.; Cicic, D.; Ali, S.
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • First-in-human phase 1/2 study of ubamatamab, a MUC16XCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer
    Meeting Abstract

    Moore, K.; Bouberhan, S.; Hamilton, E.; Liu, J. Y.; O'Cearbhaill, R.; O'Malley, D.; Papadimitriou, K.; Schröder, D.; Van Nieuwenhuysen, E.; Yoo, S. Y.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Outcomes associated with postoperative chemotherapy following pelvic exenteration for recurrent or persistent gynecologic malignancies
    Meeting Abstract

    Zammarrelli, B.; Saini, A.; Rios-Doria, E.; Yeoshoua, E.; Jewell, E.; Tew, W.; Abu-Rustum, N.; Leitao, M.; Sonoda, Y.; O'Cearbhaill, R.
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Radiation quality and workflow in NRG GY017: Anti PD-L1 (atezolizumab) as an immune primer or concurrently with RT for node positive locally advanced cervical cancer
    Meeting Abstract

    Mayadev, J.; Deng, W.; Zamarin, D.; Lankes, H.; Kim, H.; Chino, J.; Banberry, B.; Sherry, N.; Ghamande, S.; Ferguson, C.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)
    Meeting Abstract

    O'Cearbhaill, R.; Sill, M.; Duong, H.; Waggoner, S.; Grisham, R.; Backes, F.; Mannel, R.; Tanyi, J.; Powell, M.; Mathews, C.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 clinical and biomarker results
    Meeting Abstract

    Liu, J.; O'Malley, D.; Van Nieuwenhuysen, E.; Moore, K.; Hamilton, E.; Yeku, O.; Bouberhan, S.; Hou, J.; Schröder, D.; Wang, B.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save